ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Nivolumab (Primary) ; Valaciclovir (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ENSIGN
- 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
- 15 Feb 2017 Status changed from not yet recruiting to recruiting.
- 19 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Mar 2017.